Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tax Court Backs Medtronic In Transfer-Payment Dispute

This article was originally published in The Gray Sheet

Executive Summary

The ruling means a larger portion of the company’s earnings can be taxed at the lower rate applied to foreign corporations.

You may also be interested in...



Boston Scientific Plans IRS Settlement

Boston Sci plans to pay $275m to settle transfer-pricing disputes with the US Internal Revenue Service. A financial analyst views the settlement as a win for the company because it’s well below what the IRS initially sought.

Sanofi CEO Hudson Delivers An Ambitious Turnaround Agenda

CEO Paul Hudson came to Sanofi's capital markets day with big news and key messages for investors about the company's future business model. 

Sanofi Has The Fire Power For Deals, CEO Hudson Says

The company is looking at deals in the $2bn to $5bn range, CEO Paul Hudson told investors, but premiums for assets are high and Sanofi is looking at earlier-stage opportunities as a result.

Topics

Related Companies

UsernamePublicRestriction

Register

MT034870

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel